Overview

Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation, comparing individual and collective forms of litigation, and illustrating the misunderstandings between scientists and lawyers about the role of science in providing evidence for the legal system.

Full Product Details

Author:   Michael D. Green
Publisher:   University of Pennsylvania Press
Imprint:   University of Pennsylvania Press
Edition:   New edition
Dimensions:   Width: 15.20cm , Height: 2.00cm , Length: 22.90cm
Weight:   0.600kg
ISBN:  

9780812216455

ISBN 10:   0812216458
Pages:   384
Publication Date:   01 January 1998
Audience:   College/higher education ,  Professional and scholarly ,  Undergraduate ,  Postgraduate, Research & Scholarly
Format:   Paperback
Publisher's Status:   Active
Availability:   Out of stock  
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Table of Contents

Preface Acknowledgments Chapter 1-A Birth Defect Child Is Born Chapter 2-Locating Bendectin within the Mass Toxic Landscape Chapter 3-The Science of Determining Toxic Causation Chapter 4-The Food and Drug Administration Chapter 5-The Wm. S. Merrell Company Chapter 6-A Mother's Quest Chapter 7-The Mekdeci Case Chapter 8-The Unraveling of Mekdeci Chapter 9-The Proliferation of Bendectin Litigation Chapter 10-Litigating a Multidistrict Case Chapter 11-The Withdrawal of Bendectin Chapter 12-Forging a Mass Toxic Substances Trial Chapter 13-The Settlement and Unsettlement of MDL-486 Chapter 14-The MDL-486 Trial Chapter 15-Aggregative Procedure in Mass Toxic Substances Litigation Chapter 16-The Third Phase of Bendectin Litigation: Oxendine, Richardson, and the Individual Trials Chapter 17-The Legacy of Bendectin for Toxic Causation Law Chapter 18-The Lessons and Non-Lessons of Bendectin Litigation Selected Bibliography Index

Reviews

Important reading for obstetrician-gynecologists and family physicians who provide obstetrical services. -New England Journal of Medicine Should be required reading in all law schools, and should be part of continuing education activities for judges and attorneys. -Judicature

Important reading for obstetrician-gynecologists and family physicians who provide obstetrical services. -New England Journal of Medicine Should be required reading in all law schools, and should be part of continuing education activities for judges and attorneys. -Judicature

Should be required reading in all law schools, and should be part of continuing education activities for judges and attorneys. -Judicature Important reading for obstetrician-gynecologists and family physicians who provide obstetrical services. -New England Journal of Medicine

Author Information

Michael D. Green is Professor of Law at the University of Iowa.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions